South San Francisco, United States
Circle Pharma, Inc., founded in 2012, is positioned at the forefront of biotechnology with its pioneering approach to macrocyclic peptide therapeutics. Based in the United States, the company focuses on using a computational structure-based design approach to develop bioavailable therapeutics targeting critical intracellular protein-protein interactions, particularly in cancer.
Having initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP, Circle Pharma has successfully completed multiple funding rounds, most recently securing a $90.00M Series D investment from The Column Group, Euclidean Capital, and Nextech Invest in September 2024.
Circle Pharma's innovative strategy incorporates the use of proprietary algorithms to design virtual libraries of cell-permeable macrocyclic scaffolds, blending natural and synthetic elements to optimize target binding and permeability. This method not only showcases a new paradigm in drug development but also reinforces the company's leading position within the Biotechnology, Health Care, and Health and Wellness sectors.
